TB-500 (Thymosin Beta-4)
A 43-amino acid peptide fragment of thymosin beta-4, extensively researched for its roles in wound healing, tissue repair, and anti-inflammatory activity.
Overview
TB-500 is a synthetic version of the naturally occurring 43-amino acid peptide Thymosin Beta-4 (Tβ4), one of the most abundant and highly conserved peptides in the human body. Thymosin Beta-4 was originally isolated from the thymus gland and is found in virtually all tissues and cell types, with particularly high concentrations in blood platelets, wound fluid, and developing tissues.
TB-500 contains the active region of Thymosin Beta-4 responsible for its primary biological activities, including the actin-binding domain and the tissue repair sequences. Research spanning several decades has established TB-500/Tβ4 as a central regulator of cell migration, angiogenesis, inflammation, and tissue repair. The peptide’s ability to promote healing across virtually every tissue type studied has made it one of the most versatile compounds in regenerative medicine research.
Mechanism of Action
TB-500 exerts its biological effects through several well-characterized mechanisms:
- Actin Sequestration: TB-500’s primary molecular function is binding and sequestering G-actin (monomeric actin), which serves as a reservoir for rapid actin polymerization when cell migration or shape changes are needed. The key binding motif is the 17-amino acid sequence centered on the LKKTET domain.
- Cell Migration Promotion: By regulating the actin cytoskeleton, TB-500 promotes directional cell migration of endothelial cells, keratinocytes, and other cell types critical for wound healing and tissue repair.
- Angiogenesis: TB-500 is a potent promoter of new blood vessel formation, stimulating endothelial cell differentiation and tube formation through both direct effects on endothelial cells and upregulation of angiogenic growth factors.
- Anti-inflammatory Activity: Research demonstrates TB-500 downregulates pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) and chemokines while promoting anti-inflammatory mediators, contributing to resolution of inflammation at injury sites.
- Matrix Metalloproteinase Regulation: TB-500 influences MMP expression and activity, promoting controlled tissue remodeling and reducing excessive scar formation.
Key Research Findings
- Cardiac Repair: Multiple studies have demonstrated that Tβ4/TB-500 promotes cardiac repair following myocardial infarction, including activation of epicardial progenitor cells, neovascularization, and improved cardiac function in rodent models.
- Dermal Wound Healing: Research consistently shows accelerated wound closure, enhanced collagen deposition, and reduced scar formation in skin wound models treated with TB-500.
- Corneal Healing: Phase II clinical trials have investigated Tβ4 for corneal wound healing (RGN-259), demonstrating improved corneal healing rates in patients with neurotrophic keratopathy.
- Musculoskeletal Repair: Studies in tendon, muscle, and ligament injury models have shown improved healing timelines and functional outcomes with TB-500 administration.
- Neurological Research: Tβ4 has demonstrated neuroprotective and neuroregenerative effects in models of traumatic brain injury and stroke, promoting oligodendrocyte differentiation and axonal remodeling.
Research Applications
- Wound Healing Research: Studying cell migration, angiogenesis, and tissue remodeling in acute and chronic wound models.
- Cardiac Regeneration: Investigating post-infarction repair, epicardial progenitor activation, and cardiac neovascularization.
- Musculoskeletal Research: Tendon, muscle, and ligament repair studies in preclinical injury models.
- Neuroscience: Exploring neuroprotection and neural repair in TBI and stroke models.
- Anti-inflammatory Research: Studying cytokine modulation and inflammation resolution mechanisms.
Dosing Protocols (Research Use Only)
The following dosing information reflects common protocols in published research literature:
| Parameter | Details |
|---|---|
| Loading Phase | 2.0 – 5.0 mg, administered 2x per week for 4 – 6 weeks |
| Maintenance Phase | 2.0 mg, administered 2x per week |
| Cycle Duration | 8 – 16 weeks total |
| Preclinical Dose (Rodent) | 6 mg/kg in published cardiac and wound healing studies |
| Route | Subcutaneous or intramuscular injection |
This profile is provided for educational and informational purposes only. TB-500 (Thymosin Beta-4) is sold as a research chemical and is not approved by the FDA for human use. All information presented is based on published research literature and should not be construed as medical advice. Always consult qualified professionals before making any decisions related to peptide research.
Ready to Research TB-500 (Thymosin Beta-4)?
Get ≥99% purity research-grade peptides with COA from Iron Peak Peptides.